| Ytd | -57.41% | |
| 1y | 38.15% |
| Open | 12.85 | Prev Close | 12.92 | Low | 12.81 | High | 13.34 | Mkt Cap | 321.25M |
| Vol | 151.30K | Avg Vol | 151.50K | EPS | -13.80 | P/E | -0.95 | Forward P/E | -0.73 |
| Beta | -0.06 | Short Ratio | 6.15 | Inst. Own | 58.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 14.77 | 200-d Avg | 20.81 | 1yr Est | 1.00 |
LYEL News
B. Riley Securities analyst Yuan Zhi initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with
Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) has received an average rating of "Moderat
Gainers Seer (NASDAQ:SEER) shares rose 32.1% to $2.14 during Monday's pre-market session. The m
Citizens analyst Reni J. Benjamin reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Market Outpe
Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-g
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) wi
Lyell Immunopharma reports improved safety data for LYL273 in metastatic colorectal cancer and advan
Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10%
Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-g
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) wi
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(1.10) per share which beat the analy
Wall Street analysts changed outlook on top stocks. See rating changes on NKE, SMPL, WSR, NTNX, and
Top Wall Street analysts changed outlook on top names. Initiations & upgrades noted. For full ch
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.